Syngene sees quantifying a biomarker in mice brain to treat mood and anxiety disorders imperative in drug development

New modalities drive CDMO growth

Rethinking Growth Promoters Through the Lens of Green Chemistry

25 Transformative Years of Biosimilars

Syngene collaborates with biotech firm to develop bile acid modulator for cholestatic disease treatment

Antibody-drug conjugates are a significant evolution in drug development landscape: Dr. Kenneth Barr

PROTACs: Current Landscape and Their Significance in Drug Discovery

Shaping the Future of Science Through Women Leaders in India

Breaking Barriers, Driving Innovation and Shaping the Future

From The Lab To Leadership: Nurturing The Next Generation Of Women Scientists
